Variables | level | Overall | Alive | Death | P value |
---|---|---|---|---|---|
N | Â | 4522 | 3993 | 529 | Â |
Age (mean (SD)) |  | 58.77 (10.65) | 58.42 (10.73) | 61.39 (9.70) |  < 0.001 |
Sex (%) | Male | 2540 (56.2) | 2148 (53.8) | 392 (74.1) |  < 0.001 |
Female | 1982 (43.8) | 1845 (46.2) | 137 (25.9) | Â | |
Smoke (%) | No | 2393 (52.9) | 2205 (55.2) | 188 (35.5) |  < 0.001 |
Yes | 1401 (31.0) | 1165 (29.2) | 236 (44.6) | Â | |
Unknown | 728 (16.1) | 623 (15.6) | 105 (19.8) | Â | |
Marital status(%) | Married (including common law) | 4355 (96.3) | 3843 (96.2) | 512 (96.8) | 0.596 |
Divorced | 4 (0.1) | 4 (0.1) | 0 (0.0) | Â | |
Single (never married) | 58 (1.3) | 54 (1.4) | 4 (0.8) | Â | |
Unknown | 105 (2.3) | 92 (2.3) | 13 (2.5) | Â | |
Histologic_Type_ICD_O_3 (%) | Adenocarcinoma | 3530 (78.1) | 3188 (79.8) | 342 (64.7) |  < 0.001 |
Adenosquamous | 63 (1.4) | 44 (1.1) | 19 (3.6) | Â | |
Large cell carcinoma, | 25 (0.6) | 18 (0.5) | 7 (1.3) | Â | |
Neuroendocrine cancer | 54 (1.2) | 44 (1.1) | 10 (1.9) | Â | |
Non-small cell lung cancer | 10 (0.2) | 9 (0.2) | 1 (0.2) | Â | |
Sarcomatoid carcinoma | 47 (1.0) | 35 (0.9) | 12 (2.3) | Â | |
Signet ring cell carcinoma | 64 (1.4) | 45 (1.1) | 19 (3.6) | Â | |
Small cell carcinoma | 621 (13.7) | 510 (12.8) | 111 (21.0) | Â | |
Squamous cell carcinoma | 1 (0.0) | 1 (0.0) | 0 (0.0) | Â | |
Undifferentiated carcinoma | 107 (2.4) | 99 (2.5) | 8 (1.5) | Â | |
Grade (%) | other | 503 (11.1) | 496 (12.4) | 7 (1.3) |  < 0.001 |
Grade IModerately differentiated; Grade II | 1538 (34.0) | 1362 (34.1) | 176 (33.3) | Â | |
Poorly differentiated; Grade III | 1103 (24.4) | 906 (22.7) | 197 (37.2) | Â | |
Undifferentiated; anaplastic; Grade IV, | 7 (0.2) | 5 (0.1) | 2 (0.4) | Â | |
Unknown | 1371 (30.3) | 1224 (30.7) | 147 (27.8) | Â | |
Loratadine use | No | 3223 (71.3) | 2812 (70.4) | 411 (77.7) | Â |
Use | 1299 (28.7) | 1181 (29.6) | 118 (22.3) | 0.001 |